Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Core Insights - Adagene Inc. is set to present two posters at the SITC 39th Annual Meeting, focusing on its lead clinical program, ADG126, a masked anti-CTLA-4 SAFEbody, and its combination with anti-PD-1 therapy [1] Company Overview - Adagene Inc. is a clinical-stage biotechnology company specializing in novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence to meet unmet patient needs [2] - The company has established strategic collaborations leveraging its SAFEbody precision masking technology [2] Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, aimed at addressing safety and tolerability challenges in antibody therapeutics [3] - The SAFEbody technology allows for tumor-specific targeting while minimizing off-tumor toxicity, enhancing the therapeutic index of antibody treatments [3] Clinical Development - The lead clinical program, ADG126 (muzastotug), targets a unique epitope of CTLA-4 in regulatory T cells within the tumor microenvironment and is currently in phase 1b/2 studies in combination with anti-PD-1 therapy for Metastatic Microsatellite-stable Colorectal Cancer [4]